Feature | November 22, 2011| Peter Walts, M.D., and Jeff Olson, D.O.

Endoscopic Maze Technique Treats Refractory Atrial Fibrillation

St. Vincent Heart Center in Indianapolis developed a hybrid Cox maze technique that does not require open-heart surgery

Picture 1: The convergent approach utilizes trans-diaphragmatic access to the posterior of the heart for a true minimally invasive ablation procedure.

Picture 2: The comprehensive lesion pattern is achieved by a hybrid epicardial/endocardial ablation procedure.

Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 3 million Americans. Risk of AF increases with age and this number is expected to more than double over the next several decades.[1]  All AF is not the same. It is typically a progressive disease moving along a continuum from an intermittent and self-terminating (paroxysmal) arrhythmia, to one that is chronic and refractory to treatment (persistent). Symptoms vary considerably in type and severity, but commonly include shortness of breath, chest pressure, palpitations, exercise intolerance, congestive heart failure and stroke.

Antiarrhythmic medications are the initial treatment for symptomatic patients. Unfortunately, these medications are relatively ineffective and can have serious side effects.  

Use of the Cox-Maze Procedure
Surgical treatment of AF began with the Maze procedure developed by James Cox, M.D.[2] Lines of scar were created in the atria to modify the substrate responsible for the recurrence and maintenance of AF.  This is an effective but complex and relatively morbid procedure requiring cardiopulmonary bypass. Therefore, it is rarely performed except in patients needing heart surgery for another reason.
More recently, transvenous procedures have been developed and are able to identify triggers that could initiate and potentially sustain AF.[3]  Targeting these areas primarily involves isolating the pulmonary veins. This endocardial procedure is safe and allows for a quick recovery. Unfortunately, the success is limited and may require a second procedure in as many as 30 percent of patients with paroxysmal AF. In patients with persistent AF and an enlarged left atrium, transvenous ablation is a long, complex and technically demanding procedure. More importantly, there is a marked decrease in efficacy.[4]

New Version of Maze Procedure Aids Refractory Patients
So what about the large number of patients with symptomatic persistent AF, refractory to medical therapy, who would have an unacceptably high rate of recurrence following a transvenous catheter ablation and do not need heart surgery for another reason?  The ideal treatment of AF would be a truly minimally invasive procedure with results comparable to the Cox maze. This goal led to the convergence of surgical and electrophysiologic expertise to create a hybrid procedure for the treatment of symptomatic persistent AF.
Using a pericardioscope, which is passed transabdominally through the central tendon of the diaphragm, the surgeon is able to directly visualize both atria, including the posterior left atrium and both sets of pulmonary veins (Picture 1).

A malleable, 3 cm-long, irrigated radiofrequency coil is passed through the pericardioscope and used to create linear lines of ablation. Vacuum assistance ensures complete and stable tissue contact as the myocardium is drawn with suction into the coil. By connecting these lesions, which can be easily visualized, the pulmonary veins and posterior left atrium are isolated, compartmentalizing the atrium as with the open maze procedure.

After completion of the endoscopic epicardial ablation, as part of the same procedure, the electrophysiologist (EP), using standard transseptal catheters, is able to map the left atrium, confirm conduction block across the pulmonary vein antrum and fill in any gaps that exist in the epicardial pattern. These are typically found at the pericardial reflections and superior aspect of the left superior pulmonary vein (Picture 2).

As isolation of the pulmonary veins and posterior wall lesions are already nearly complete, the time spent on endocardial ablation is reduced dramatically, decreasing procedural risk to the patient and exposure to fluoroscopy. This also allows the EP to focus on triggers located outside the usual location and ablation of left atrial and right atrial isthmus if necessary, depending on the type of AF.

This is borne out by our early success with 75 percent freedom from AF off antiarrhythmics at six months in patients with dilated left atria and persistent AF who have already failed medical therapy and, in many cases, prior catheter ablation. As we know from Cox’s data, additional linear lines will be needed to interrupt persistent macro-reentrant circuits, which likely account for the failures. With this technology and collaboration, we and others continue to pursue that goal.

Endoscopic EP Technique Offers Benefits
Aside from the benefit to the patient provided by a more complete ablation in less time, the collaboration between EPs and surgeons has led to many secondary gains, including better understanding of disease and different approaches to treatment, realization of common interests and development of healthy collegial relationships, which spill over to the rest of the cardiology department.

This multidisciplinary approach allows for the truly minimally invasive isolation of the pulmonary veins and posterior left atrium with no incision on the chest, no cardiopulmonary bypass, decreased morbidity and intra-operative confirmation of lesion success.             

Editor’s note: Peter Walts, M.D., is a cardiothoracic surgeon and Jeffrey Olson, D.O., is a cardiac electrophysiologist at St. Vincent Heart Center of Indiana in Indianapolis, Ind.

1. Miyasaka Y, et al. “Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980-2000 and implications on the projections for future prevalence.” Circulation. 2006;114:119-125
2. Cox, JL. “The first Maze procedure.” J Thorac Cardiovasc Surg. 2011;141:1093-7
3. Haissaguerre M, Jais P, Shah DC, et al. ”Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.” N Engl J Med. 1998;339:659-66      
4. Helms AS, et al. “Relation of left atrial volume from three dimensional computed tomography to atrial fibrillation recurrence following ablation.” Am J Cardiol. 2009;103:989-93

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems | December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems | October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems | October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems | August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems | July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems | May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems | May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems | February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems | January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems | November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init